Importer vs Indian Manufacturer Pathways for Biologicals in India: Key Regulatory Differences

One of the most consequential strategic decisions for any global Biological product company entering India is whether to proceed as an importer or establish local manufacturing. This decision has profound implications for Regulatory timelines, clinical data requirements, dossier expectations, commercial positioning, and long-term market competitiveness. India’s Regulatory framework under the New Drugs and Clinical Trials (NDCT) Rules, 2019 treats these two pathways distinctly, and navigating the differences requires a clear-eyed Regulatory strategy from day one.

This article provides a comprehensive comparative analysis of the Importer and Indian manufacturer pathways for Biological products, helping global biotech and Pharmaceutical companies make an informed entry decision for the Indian market.

1. The Fundamental Distinction: Who Holds Regulatory Responsibility

Under CDSCO’s framework, Biological products can be registered in India either by a foreign manufacturer through a licensed Indian Importer or by a domestic manufacturer producing the product in India. The pathway chosen determines who holds manufacturing site accountability, who interfaces with CDSCO for GMP compliance, and how clinical bridging requirements are structured.

For Imported Biologicals, a Local Authorized Agent (LAA) or Import licensee,  typically holding  Form 20B/21B, acts as the regulatory bridge between the foreign manufacturer and CDSCO. The foreign manufacturing site must hold a valid GMP certificate from a recognised authority (WHO, EMA, USFDA, etc.) or be subject to CDSCO inspection. For Indian manufacturers, the domestic manufacturing site is directly under CDSCO and State Drug Authority jurisdiction.

2. Import Licensing Pathway

Regulatory Approvals Required

A foreign Biological product seeking to enter India via the Import route must secure:

1. New Drug Approval (NDA) from CDSCO / DCGI under CT-18 (for market authorization))
2. Registration Certificate (in Form 40) and Import licence (Form 10) ) under the Drugs and Cosmetics Rules
3. GMP compliance certificate from a recognised authority for the foreign manufacturing site
4. Labelling adaptation for India (Schedule D(II) and related provisions)

If the biological product is already approved in a reference jurisdiction (US, EU, Japan, Australia, Canada), CDSCO may waive or reduce Phase I and Phase II clinical trial requirements. However, Phase III bridging trials in Indian patients are typically required unless the product qualifies for an accelerated pathway.

Local Authorized Agent (LAA) Role

The LAA carries full Regulatory accountability in India,  maintaining post-marketing surveillance, filing adverse event reports to PvPI, managing import documentation, and serving as the primary point of contact for CDSCO. Selecting a credible, CDSCO-experienced LAA is one of the most critical success factors for foreign biological importers.

3. Indian Manufacturer Pathway

Regulatory Approvals Required

An Indian manufacturer producing a biological product domestically must navigate:

5. Manufacturing licence from the State Drug Authority (Form 28D or 28DA depending on the facility)
6. CDSCO New Drug registration under the NDCT Rules, 2019 (Form CT-21)
7. RCGM approval, if the product is recombinant (rDNA-derived), is required before GMP manufacturing for clinical and commercial batches
8. GEAC clearance in specific cases involving genetically modified organisms
9. SEC review for complex biologicals

For Biosimilars manufactured in India, the Similar Biologics Guidelines apply  requiring full physicochemical, biological, and clinical comparability exercises against the Indian reference biologic.

4. Comparative Analysis: Key Differences

Table 1

5. CTD Localisation: Critical Differences

For Importers, CTD localisation primarily involves adapting Module 1 for India-specific requirements, viz.,  labelling, prescribing information, RMP addendum, and PvPI commitments. The foreign Module 3 (quality) dossier may largely be retained if GMP is from a recognised authority.

For Indian manufacturers, Module 3 must reflect the Indian manufacturing site in full process validation, batch analysis, stability data under Zone IVb conditions (40°C/75% RH), and Indian reference standards. For biosimilars, a full comparability exercise against the Indian reference biologic is mandatory.

6. Strategic Recommendations for Global Companies

The optimal strategy for most global biological companies is a phased approach:

10. Phase 1- Market Entry: Enter via the import pathway to establish commercial presence and generate Indian patient data without the capital burden of local manufacturing.
11. Phase 2 – Market Deepening: Evaluate CMO partnerships or tech transfer arrangements as volumes grow, leveraging India’s PLI scheme for Pharmaceuticals.
12. Phase 3 -Strategic Manufacturing: Establish own Indian manufacturing if volumes and commercial returns justify the capital deployment,  enabling access to government tenders, export markets, and the Make in India positioning advantage.

Conclusion

Understanding the Regulatory, Clinical, and commercial distinctions between the Importer and Indian manufacturer pathways is foundational to any successful Biologicals market entry strategy in India. Neither pathway is inherently superior; however, the right choice depends on your product profile, global approvals status, timeline ambition, and long-term commercial objectives.

CliniExperts Services has guided numerous global biological companies through both pathways,  from regulatory strategy design and LAA selection to CTD localisation, SEC interaction, and market authorisation. Our multi-authority expertise across CDSCO, RCGM, DBT, and State Drug Authorities ensures your India biologicals journey is efficient, compliant, and commercially optimised.

Ready to navigate India’s biological regulatory landscape? Contact CliniExperts Services for a complimentary regulatory strategy consultation. Visit contact@cliniexperts.com